Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9921109 | European Journal of Pharmacology | 2005 | 8 Pages |
Abstract
Alvimopan is a novel peripheral μ opioid antagonist in clinical development for the management of post-operative ileus and opioid-induced bowel dysfunction. We hypothesized that the long duration of action of alvimopan might be related to a slower dissociation rate from the μ opioid receptor compared to other shorter acting antagonists. The dissociation rate of alvimopan from the μ opioid receptor (t1/2 = 30-44 min) was comparable to that of the long acting partial agonist buprenorphine (t1/2 = 44 min), but was slower than those of the antagonists naloxone (t1/2 = 0.82 min) and N-methylnaltrexone (t1/2 = 0.46 min). Also, increases in the apparent affinities and potencies of buprenorphine and alvimopan, but not of naloxone and methylnaltrexone, were observed upon preincubation with the μ opioid receptor. Consistent with its long duration of action, alvimopan has a slow dissociation rate from the μ opioid receptor compared to other shorter acting antagonists and may be more potent if administered prior to dosing with exogenous opioids.
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Joel A. Cassel, Jeffrey D. Daubert, Robert N. DeHaven,